BEAM: 金宾酒业

BEAM新闻

• 10:14 HC Wainwright & Co. 重申对 Beam Therapeutics 的“买入”评级，维持 80 美元目标价
• 10:14 HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
• 12:45 Top 10 Powder Keg Stocks Where Short Sellers Are Sitting on a Fuse
• 11:14 Beam Therapeutics将在第33届ESGCT年会上公布正在进行的1/2期临床试验BEAM-301用于治疗糖原贮积病Ia型的初步数据
• 11:14 Beam Therapeutics To Present Initial Data From Ongoing Phase 1/2 Clinical Trial Evaluating BEAM-301 For Treatment Of Glycogen Storage Disease Type Ia At 33rd Annual Congress Of ESGCT
• 19:33 Reflection debuts Beam, an open-weight AI model to rival Chinese models at lower compute cost
• 13:00 Temporary Weakness in Intellia Stock Seems Like a Buying Opportunity
• 11:30 Beam Therapeutics: Ignore The Anthropic Noise And Focus On Clinical Progress (NASDAQ:BEAM)
• 21:02 As Claude Enters the Gene-Editing Arena, There’s Still a Long-Term Case for BEAM Stock
• 20:00 Prime Medicine: A Buy Due To BLA Filing H1 '27 And In Vivo Therapy Development (PRME)
• 18:00 Squeeze Watch: 10 Stocks With Over 33% Short Interest
• 18:59 Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing (CRSP)
• 14:40 凯西·伍德大举投资生物科技：持有她最新股票的5只交易所交易基金 (ETFs)
• 14:40 Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
• 13:44 Can Intellia's Pipeline Progress Create Long-Term Value Amid Rivalry?
• 16:53 Gene-Editing Powerhouse And Its Rivals Surge Toward A Breakout
• 20:11 Beam Therapeutics: Market Selling Phase 2 AATD Data Is Understandable, In My View (BEAM)